SCHEMBL2944837

SCHEMBL2944837

COC(=O)CCCCNC(=O)COCCOS(C)(=O)=O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 2/20 0.38
CA12 O43570 3/20 0.36
CA14 Q9ULX7 3/20 0.36
RECQL P46063 1/20 0.36
CA2 P00918 2/20 0.35
CA7 P43166 2/20 0.35
CA9 Q16790 2/20 0.35
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
CA1 P00915 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA13 Q8N1Q1 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
GLP1R P43220 5/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2943540 0.81 TSHR (0.44) EPHX2LMNATSHRRECQL
SCHEMBL12092176 0.77 TSHR (0.43) LMNATSHRCA12CA14FNTA
SCHEMBL1193812 0.75 TSHR (0.58) LMNATSHRCA12CA14RECQL
SCHEMBL12092174 0.75 TSHR (0.44) LMNATSHRCA12CA14CA2
SCHEMBL11885392 0.75 TSHR (0.58) LMNATSHRCA12CA14RECQL
SCHEMBL2944258 0.74 LMNA (0.52) EPHX2LMNATSHRRECQL
SCHEMBL11843652 0.74 GAA (0.50) EPHX2
SCHEMBL27225836 0.73 TSHR (0.50) EPHX2LMNATSHRCA12CA14
SCHEMBL2771342 0.73 RECQL (0.63) EPHX2LMNATSHRRECQL
SCHEMBL13376980 0.71 RECQL (0.61) EPHX2LMNATSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 US disclosed
US-7375119-B2 Amide type carboxamide derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-05-20 US disclosed
US-20060287329-A1 Amide type carboxamide derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-12-21 US disclosed
EP-1666455-A1 AMIDE TYPE CARBOXAMIDE DERIVATIVE TANABE SEIYAKU CO., LTD. (JP) 2006-06-07 EP disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287329-A1 Amide type carboxamide derivative F12, F11, F13A1 EPHX2 2962/4885LMNA 1114/4885TSHR 490/4885
US-20090156803-A1 Condensed furan compounds F2, F12, F11 EPHX2 1001/4885LMNA 832/4885TSHR 3368/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 EPHX2 873/4885LMNA 1796/4885TSHR 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.